Nureflex Junior

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nureflex Junior

Nureflex Junior is a non-prescription pediatric medicinal product that serves as a systemic relief agent for pain, fever, and inflammation in children. Its identity is fundamentally defined by its active ingredient, Ibuprofen, which places it within the drug class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The NSAID classification is key to understanding the drug's triple action profile.


Quick Facts

Property Description
Active Ingredient Ibuprofen
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Form Oral Suspension (Liquid)
Route Oral (via mouth)
General Purpose Symptomatic relief of pain, fever, and inflammation

Definition and Pharmacological Class

Nureflex Junior is an oral, single-active-ingredient medicine that provides symptomatic relief by reducing elevated body temperature, alleviating pain, and mitigating inflammatory responses. The medication belongs to the NSAID pharmacological group, which means its action is based on inhibiting the body’s production of certain chemical signals responsible for pain and fever.

The active component, Ibuprofen, is a synthetic compound derived from propanoic acid. Unlike certain other analgesic and antipyretic agents, the NSAID classification endows Ibuprofen with a significant anti-inflammatory capability, allowing it to address underlying inflammation (such as swelling or redness) in addition to providing fever-reducing (antipyretic) and pain-relieving (analgesic) effects. This broad scope defines its general therapeutic purpose in pediatric care.


Composition, Form, and the 'Junior' Formulation

This product is formulated as an oral suspension, a liquid medicine where the active Ibuprofen is precisely dispersed within an aqueous-based vehicle. The specific designation of "Junior" indicates that this formulation is designed for use in pediatric patients. This formulation type is utilized for its suitability in pediatric administration.

The liquid formulation is a crucial identity feature, setting it apart from solid forms like tablets or capsules. This format makes oral administration easier for children who may not be able to swallow pills, and it is engineered to allow for accurate weight- or age-based dosing through small, incremental measures.

Regulatory References

  1. paediatric medicines overview
  2. Pain Management Medications (Analgesics)
  3. Anti-Inflammatory Properties of NSAIDs (NIH)
  4. Antipyretic Properties of NSAIDs (NIH)
  5. Analgesic Properties of NSAIDs (NIH)
  6. Paediatric Medicines Overview (EMA)
  7. Pediatric Drug Dosing (NIH)

What side effects are possible with Nureflex Junior?

Possible side effects and safety information

The safety profile of Nureflex Junior, based on its active ingredient Ibuprofen, is formally defined in government regulatory documents by classifying potential adverse reactions according to frequency and the body system affected. This classification ranges from very common effects to those considered very rare.

Officially Documented Adverse Reactions by Frequency

Frequency Category Examples of Listed Effects System-Organ Class Focus
Common Nausea, vomiting, dyspepsia, abdominal pain Gastrointestinal disorders
Uncommon Headache, dizziness, skin rashes, urticaria Nervous system and Skin
Rare Gastrointestinal ulceration and bleeding Gastrointestinal disorders
Very Rare Severe cutaneous reactions (SCARs), acute renal failure Skin, Renal, and Hepatic

Serious adverse reactions officially documented in regulatory labels include Gastrointestinal Ulceration and Bleeding, which can occur without warning. Additionally, a risk of serious Arterial Thrombotic Events (such as myocardial infarction or stroke) is noted, specifically associated with high doses and prolonged use. The pharmacological effect of reducing fever and inflammation may also temporarily mask signs of an underlying infection.

Safety Considerations and Limitations

Official safety documents define specific patient groups requiring caution or where use is restricted. Older adults are cited as having a higher absolute risk of serious gastrointestinal complications. Individuals with pre-existing conditions, such as severe heart failure or active gastrointestinal haemorrhage, are generally contra-indicated. The risk of serious adverse effects, including those affecting the cardiovascular and gastrointestinal systems, is explicitly linked to increasing dosage and duration of exposure.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

Overdose Scope

Nureflex Junior contains ibuprofen. Taking more than the recommended maximum dose is considered an overdose and is potentially very dangerous. Symptoms of overdose most commonly occur within four hours of ingestion and can include nausea, vomiting, epigastric pain, and occasionally tinnitus (ringing in the ears) or headache.

More severe toxicity affects the Central Nervous System (CNS) and can present as drowsiness, disorientation, confusion, seizures, or coma. Other life-threatening effects are acute renal failure, metabolic acidosis, and hypotension (low blood pressure).

Emergency Actions

  • Go to the nearest Accident and Emergency (A&E) department immediately if you or someone else has taken more than the recommended maximum dose of this medicine, even if you are feeling well and have no symptoms. Do not wait for symptoms to develop.
  • Contact a Poison Center for urgent advice.
  • Immediate medical attention is required for any signs of severe toxicity, such as difficulty breathing, convulsions, low blood pressure, or loss of consciousness.

Older people and those with pre-existing gastrointestinal conditions are at increased risk for severe gastrointestinal complications like bleeding. Prompt medical monitoring and supportive care are essential for a favorable prognosis in all cases of overdose.

Therapeutic Uses of Nureflex Junior

What Nureflex Junior Treats: Main Uses and Benefits

The active ingredient in Nureflex Junior is generally considered relevant in the management of distressing symptoms in children. Medicines of this type are utilized as part of symptomatic management across key therapeutic domains.

Symptomatic Relief and Core Indications

Nureflex Junior is applied in clinical settings that involve symptoms related to systemic imbalance, including elevated body temperature (fever) and symptoms associated with acute episodes, which can occur during common cold or flu-like presentations. It is commonly used to help with specific, localized symptoms, including headache, toothache, earaches, and discomfort from sore throats. Additionally, the therapeutic scope is relevant for symptoms of elevated body temperature (fever), physical discomfort (including headache, toothache, and earache), and signs of inflammation (such as swelling and soreness).

Benefit and Clinical Context

The medicine is relevant for symptoms linked to inflammatory or irritative states, such as minor musculoskeletal discomfort from sprains, strains, or post-immunization soreness. By addressing symptoms related to systemic imbalance and physical discomfort, the medication generally provides supportive relief that contributes to improved comfort during periods of acute illness. Applied during phases when symptoms become more noticeable, it assists with maintaining stability and supports the patient during difficult episodes by easing the overall symptom load.


Quick Fact: Symptomatic Domains
Symptom Relief: Elevated Body Temperature (Fever)
Discomfort Easing: Physical Pain (Headache, Toothache, Earache)
Supportive Management: Inflammation (Swelling, Soreness)

Eligibility and Restrictions for Use

Who can and cannot use Nureflex Junior?

This section outlines the official population eligibility and exclusion rules for Ibuprofen oral suspension, as defined by government regulatory documents.

Eligibility Scope

Classification Rule Regulatory Basis
Allowed Population Pediatric patients, typically from 6 months up to 12 years. Some authorities permit use from mathbf3 months if the child weighs at least mathbf5 kg (11 lbs). FDA, EMA SmPC
Conditional Use Children who are dehydrated (e.g., from vomiting/diarrhea) or have certain pre-existing conditions (e.g., kidney, liver, or heart disease) must consult a doctor before use. FDA, EMA SmPC
Age-Prohibited Use is not recommended for general over-the-counter administration in children under mathbf6 months of age. Use in children under mathbf3 months is generally contraindicated. FDA OTC Label, NHS

Absolute Contraindications

The medicine must not be used in children who have:

  • A known allergy or hypersensitivity to Ibuprofen, Aspirin, or any other NSAID (Non-Steroidal Anti-Inflammatory Drug).
  • A history of gastrointestinal bleeding or perforation related to previous NSAID use.
  • Active or recurrent stomach ulcers or bleeding.
  • Severe heart failure, severe hepatic failure (liver), or severe renal failure (kidney).
  • Active bleeding of the brain (cerebrovascular) or other uncontrolled bleeding disorders.

Eligibility-Related Restriction

For symptoms of sore throat, if the condition is severe or persistent, or accompanied by high fever, headache, nausea, and vomiting, a doctor must be consulted promptly, and use should generally not exceed two days.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Nureflex Junior (Ibuprofen) based on the mechanism of action and resulting outcomes, primarily focusing on pharmacodynamic and pharmacokinetic effects with other co-administered substances. The simultaneous administration of Ibuprofen is formally contraindicated with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, and with Aspirin at daily doses exceeding 75 mg due to the significantly increased risk of adverse gastrointestinal events.


Pharmacokinetic and Exposure Effects

Co-administration with CYP2C9 inhibitors (e.g., Voriconazole, Fluconazole) may lead to an increase in Ibuprofen plasma concentrations left(Cmax and AUC ight) due to reduced metabolic clearance. Furthermore, Ibuprofen is documented to reduce the renal clearance of medicines such as Lithium, Methotrexate, and Digoxin, resulting in increased plasma concentrations and potential accumulation of these specific agents.


Pharmacodynamic and Timing Constraints

Ibuprofen co-administration with anticoagulants (e.g., Warfarin) or SSRIs carries an officially documented increased risk of hemorrhage due to reinforcing pharmacodynamic effects. When taken with diuretics or ACE Inhibitors, a reduced efficacy of the antihypertensive agent and a heightened risk of renal function deterioration is noted in the official labeling, particularly in the elderly population. To avoid the interference of Ibuprofen with the anti-platelet effect of immediate-release low-dose Aspirin, a mandatory timing separation of at least 8 hours before or 30 minutes after the Aspirin dose must be observed.

Mechanism of Action

Nureflex Junior (ibuprofen) functions as a non-steroidal anti-inflammatory drug (NSAID) by competitively inhibiting the activity of cyclooxygenase (COX) enzymes. It non-selectively blocks both the constitutive COX-1 isoform and the inducible COX-2 isoform, thereby preventing enzymatic catalysis. The primary site of action is the active channel of the COX enzyme.

This inhibition prevents the conversion of arachidonic acid into prostanoids. This limits the biosynthesis of key signaling lipids, including prostaglandins (PGs) and thromboxanes. The subsequent decrease in local PG concentrations interrupts the inflammatory signal transduction pathway, leading to a reduction in the sensitization of peripheral nociceptors.

The downstream physiological consequence includes the modulation of the hypothalamic thermoregulatory center, which alters the febrile response, and an overall attenuation of tissue swelling and edema formation resulting from localized inflammatory mediator activity.

Dosage and Administration Information

Official Administration Guidelines

Nureflex Junior (Ibuprofen oral suspension, e.g., 100 mg/5 mL) is for oral and short-term use only. The administration protocol is strictly based on the child's age or weight to ensure accurate dosing. The maximum daily total dose should not exceed 40 mg/kg of body weight.


Dosing and Frequency

Age/Weight Group Single Dose (Example 100 mg/5 mL) Max Doses in 24 Hours Minimum Interval
3–5 months (ge 5 kg) 2.5 mL (50 mg) 3 4 hours
6–11 months 2.5 mL (50 mg) 3 to 4 4 hours
1–3 years 5 mL (100 mg) 3 4 to 6 hours
4–6 years 7.5 mL (150 mg) 3 6 to 8 hours
  • Duration: Do not give this medicine for more than 3 days unless otherwise advised by a healthcare professional. For infants 3–5 months, do not use for more than 24 hours.
  • Post-Immunisation Fever: A separate schedule applies: 2.5 mL (50 mg) dose, followed by one further 2.5 mL dose only after 6 hours, if required. Do not give more than 2 doses in 24 hours for this specific use.

Administration Requirements

  • Preparation: Shake the bottle well before measuring each dose. Multiple concentrations of oral suspension exist; always confirm the strength of the product you are using.
  • Measurement: Use the dosing syringe or cup that is provided with the product. Kitchen spoons must not be used for measurement to avoid inaccurate dosing.
  • Timing: The medicine can be administered with food or milk to reduce the potential for stomach upset.

Recent Clinical Evidence

Nureflex Junior: Recent Clinical Evidence


Evidence for Pain Relief in Children (Analgesia)

Research has examined the use of Nureflex Junior in children for outcomes related to physical discomfort, used in research contexts involving fluctuating or unstable symptoms. Studies have evaluated the medicine in settings relevant in trials assessing short-term or episodic symptom patterns, like pain after common procedures, headaches, or dental pain. These studies help show what has been observed so far regarding how Nureflex Junior was evaluated regarding pain outcomes and how symptoms evolved in the observed populations during the study period.

The findings describe patterns related to temporary changes in patient-reported outcomes describing perceived discomfort. Research describes that for acute discomfort, studies monitored temporary physiological imbalance and show patterns related to certain changes in symptom intensity over defined time intervals. However, it is important to note that results apply only to the populations studied, and evidence quality varies across studies when comparing different types of physical discomfort.

Evidence for Reducing Fever (Antipyresis)

Nureflex Junior was studied in research scenarios involving temporary physiological imbalance, specifically those associated with fever. Research examined temporary physiological imbalance and systemic or functional imbalance by monitoring body temperature. These studies were often conducted during periods of increased symptom activity where fever symptoms become more noticeable.

Long-term Studies and Follow-up

Research has examined the effects of Nureflex Junior on outcomes monitored in observational settings evaluating daily-life functioning when studied over defined time intervals. Currently, evidence is limited regarding the results of research examining responses over defined time intervals, as long-term follow-up durations were limited in many studies. This section will summarize what is known and what is still uncertain about the patterns observed in studies and any extended-duration data.

Key Studies & References

  1. Ibuprofen versus acetaminophen for pain in children: a systematic review and meta-analysis
  2. Systematic review of the long-term safety profile of non-steroidal anti-inflammatory drugs (NSAIDs) in the pediatric population

Frequently Asked Questions (FAQ)

Common questions about Nureflex Junior (FAQ)

Q: Can I take this medicine if I have a history of stomach ulcers?

According to the official product information, this medicine should generally not be used if you have a history of stomach bleeding or ulcers. These conditions can increase the risk of serious side effects. If you have a history of stomach ulcers or bleeding, consultation with a healthcare professional is advised before use.

Q: Does this drug cause drowsiness or make me feel tired?

Official documentation lists known side effects related to the nervous system. However, the regulatory documentation does not commonly list drowsiness or fatigue as a frequent or common side effect associated with the use of this medication.

Q: What is the proper way to store this medicine?

The official drug label provides specific guidance for storing the product to maintain its quality and efficacy. Official labeling directs that the medicine be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).

Q: Can children 5 years old take the adult tablet formulation?

Regulatory documents explicitly define the age groups for which each formulation is intended. The product label specifies that this formulation is not intended for children under 12 years of age. Always check the directions section for the appropriate age and dose.

Q: Does this medicine interact with blood pressure medication?

The official product information contains a section dedicated to drug-drug interactions. It lists known clinically significant interactions between this medicine and several other types of medications, including certain blood pressure medicines. If you are taking prescription medications, consulting the official interaction information or discussing use with a healthcare professional is recommended.

Q: Can I take this for a migraine headache?

The regulatory documents define the approved uses, or 'indications,' for the product. This medicine is formally approved for the temporary relief of minor aches and pains, which generally covers headaches. The official label does not specifically name migraines as an indication.

How should Nureflex Junior be stored and disposed of?

How to Store and Dispose of Nureflex Junior

Storage Conditions and Protection

Nureflex Junior (ibuprofen oral suspension) must be stored at controlled room temperature, typically not above 25°C (77°F), as required by regulatory labeling. The product must be protected from excess heat, moisture, and direct light and must not be frozen.

Packaging, Stability, and Safety

It is mandatory to keep the medicine in its original, tightly closed container to preserve product integrity and maintain child resistance. The product must always be stored out of the sight and reach of children.

Once the bottle is opened, the in-use shelf-life for the oral suspension is generally limited to six months.

Disposal Requirements

Any expired or unused Nureflex Junior product must be disposed of in accordance with local regulatory requirements or through an official drug take-back program. The medicine should not be disposed of in household trash or poured down a sink or toilet unless explicitly instructed to do so by governmental disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nureflex Junior found in:

A-Z Index: